[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Sana Biotechnology's Burn Rate Continues While the Market Waits for Something Clinical

Sana Biotechnology Inc (SANA) reports second-quarter 2026 earnings on August 10, 2026, with analysts expecting continued losses as the clinical-stage biotech advances its pipeline of engineered cell therapies. The central question: can SANA demonstrate meaningful clinical progress and improved cost discipline to justify its current valuation, or will execution challenges and cash burn concerns continue to weigh on investor sentiment? With the stock trading near multi-year lows and analyst opinion signals deteriorating sharply in recent weeks, this report arrives at a pivotal moment for the company's credibility.

Sana Biotechnology is a clinical-stage biotechnology company focused on developing engineered cell therapies for cancer, diabetes,...

Fundamentals

See More
  • Market Capitalization, $K 979,588
  • Shares Outstanding, K 278,292
  • Annual Sales, $ 0 K
  • Annual Income, $ -244,170 K
  • EBIT $ -248 M
  • EBITDA $ -236 M
  • 60-Month Beta 2.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.72

Options Overview Details

View History
  • Implied Volatility 111.98% (+5.84%)
  • Historical Volatility 64.55%
  • IV Percentile 37%
  • IV Rank 29.52%
  • IV High 212.15% on 02/05/26
  • IV Low 70.03% on 01/27/26
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 886
  • Volume Avg (30-Day) 626
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 34,245
  • Open Int (30-Day) 32,990
  • Expected Range 3.52 to 3.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 6
  • High Estimate $-0.13
  • Low Estimate $-0.17
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +16.17%
on 07/29/26
4.21 -16.39%
on 07/08/26
-0.60 (-14.56%)
since 07/07/26
3-Month
2.61 +34.87%
on 06/08/26
4.21 -16.39%
on 07/08/26
+0.02 (+0.57%)
since 05/07/26
52-Week
2.61 +34.87%
on 06/08/26
6.55 -46.26%
on 10/15/25
+0.55 (+18.52%)
since 08/07/25

Most Recent Stories

More News
Sana Biotechnology's Burn Rate Continues While the Market Waits for Something Clinical

Barchart Research What to Expect from SANA Earnings SANA Generated August 7, 2026 Current Price $3.52 EPS Estimate $$-0.15 Consensus Rating Strong Buy Average Move 5.77% Sana Biotechnology's Burn Rate...

SANA : 3.52 (+3.23%)
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

SANA : 3.52 (+3.23%)
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025 Seminal Study Successfully Achieved Primary...

SANA : 3.52 (+3.23%)
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation...

SANA : 3.52 (+3.23%)
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

SANA : 3.52 (+3.23%)
Sana Biotechnology to Present at June 2026 Investor Conferences

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 3.52 (+3.23%)
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold...

SANA : 3.52 (+3.23%)
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of...

SANA : 3.52 (+3.23%)
Sana: Q1 Earnings Snapshot

Sana: Q1 Earnings Snapshot

SANA : 3.52 (+3.23%)
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

SANA : 3.52 (+3.23%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 3.71
2nd Resistance Point 3.63
1st Resistance Point 3.57
Last Price 3.52
1st Support Level 3.44
2nd Support Level 3.36
3rd Support Level 3.30

See More

52-Week High 6.55
Fibonacci 61.8% 5.04
Fibonacci 50% 4.58
Fibonacci 38.2% 4.12
Last Price 3.52
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.